Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ataru Igarashi

Showing results (1-10 of 223) with videos related to

Pageof 23
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|November 30, 2022
[Current Status of Formulary in Japan and the Assessment of Various Value Components of Medicines]Ataru Igarashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 15, 2014
[Pharmacoeconomics of molecular targeting drugs]Ataru Igarashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 17, 2023
[Life and Money? Life or Money? -Health Economic Assessment and Value Assessment for Oncology Medications]Ataru Igarashi
Expert Review of Pharmacoeconomics & Outcomes Research|August 30, 2022
Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interviewAtaru Igarashi, Shunya Ikeda
Journal of Medical Economics|January 21, 2022
Impact of reimbursement restriction on drug market sales under the National Health Insurance in JapanHiroaki Mamiya, Ataru Igarashi
Journal of Medical Economics|August 27, 2021
Determinants of market prices for drugs under Japan's national health insuranceHiroaki Mamiya, Ataru Igarashi
Journal of Market Access & Health Policy|March 27, 2026
Updated Conversion Table for the Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE"Akina Takami, Ataru Igarashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2016
[Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective]Ayako Fukuda, Ataru Igarashi
Journal of Medical Economics|October 22, 2024
Analysis of factors associated with premiums for reimbursed medical devices in JapanMichael LoPresti, Ataru Igarashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 1, 2005
[Anti-rheumatoid biologics and pharmacoeconomic evaluation]Kiichiro Tsutani, Ataru Igarashi
Pageof 23

Showing results (1-10 of 223) with videos related to

Sort By:
Pageof 23
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|November 30, 2022
[Current Status of Formulary in Japan and the Assessment of Various Value Components of Medicines]Ataru Igarashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|July 15, 2014
[Pharmacoeconomics of molecular targeting drugs]Ataru Igarashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 17, 2023
[Life and Money? Life or Money? -Health Economic Assessment and Value Assessment for Oncology Medications]Ataru Igarashi
Expert Review of Pharmacoeconomics & Outcomes Research|August 30, 2022
Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interviewAtaru Igarashi, Shunya Ikeda
Journal of Medical Economics|January 21, 2022
Impact of reimbursement restriction on drug market sales under the National Health Insurance in JapanHiroaki Mamiya, Ataru Igarashi
Journal of Medical Economics|August 27, 2021
Determinants of market prices for drugs under Japan's national health insuranceHiroaki Mamiya, Ataru Igarashi
Journal of Market Access & Health Policy|March 27, 2026
Updated Conversion Table for the Multiple Criteria Qualitative Value-Based Pricing Framework "MARIE"Akina Takami, Ataru Igarashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2016
[Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective]Ayako Fukuda, Ataru Igarashi
Journal of Medical Economics|October 22, 2024
Analysis of factors associated with premiums for reimbursed medical devices in JapanMichael LoPresti, Ataru Igarashi
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 1, 2005
[Anti-rheumatoid biologics and pharmacoeconomic evaluation]Kiichiro Tsutani, Ataru Igarashi
Pageof 23